GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » EBIT per Share

ME Therapeutics Holding (XCNQ:METX) EBIT per Share : C$-0.30 (TTM As of Feb. 2024)


View and export this data going back to 2023. Start your Free Trial

What is ME Therapeutics Holding EBIT per Share?

ME Therapeutics Holding's EBIT per Share for the three months ended in Feb. 2024 was C$-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2024 was C$-0.30.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for ME Therapeutics Holding's EBIT per Share or its related term are showing as below:

XCNQ:METX's 3-Year EBIT Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

ME Therapeutics Holding's EBIT for the three months ended in Feb. 2024 was C$-0.14 Mil.

ME Therapeutics Holding EBIT per Share Historical Data

The historical data trend for ME Therapeutics Holding's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ME Therapeutics Holding EBIT per Share Chart

ME Therapeutics Holding Annual Data
Trend Aug22 Aug23
EBIT per Share
-0.01 -0.28

ME Therapeutics Holding Quarterly Data
Aug22 Dec22 May23 Aug23 Nov23 Feb24
EBIT per Share Get a 7-Day Free Trial - -0.15 -0.13 -0.02 -0.01

ME Therapeutics Holding EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

ME Therapeutics Holding's EBIT per Share for the fiscal year that ended in Aug. 2023 is calculated as

EBIT per Share(A: Aug. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-6.513/23.561
=-0.28

ME Therapeutics Holding's EBIT per Share for the quarter that ended in Feb. 2024 is calculated as

EBIT per Share(Q: Feb. 2024 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.143/23.589
=-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Feb. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ME Therapeutics Holding  (XCNQ:METX) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

ME Therapeutics Holding EBIT per Share Related Terms

Thank you for viewing the detailed overview of ME Therapeutics Holding's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

ME Therapeutics Holding (XCNQ:METX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ME Therapeutics Holding Inc (XCNQ:METX) » Definitions » EBIT per Share
Comparable Companies
Traded in Other Exchanges
Q9T:Germany
Address
177 Robson Street, Vancouver, BC, CAN, V6B 0N3
Website
https://www.metherapeutics.com
ME Therapeutics Holding Inc operates its business through ME Therapeutics. It is a preclinical-stage biotechnology company working on novel cancer-fighting drugs in the field of Immuno-Oncology (IO). It is developing preclinical data for its myeloid-targeted candidate assets using validated cancer models.

ME Therapeutics Holding (XCNQ:METX) Headlines

No Headlines